RNF43 and nonpapillary renal cell carcinoma: Additionally, lower RNF43 expression was observed in pazopanib- or sunitinib-resistant ccRCC cell lines (786-O-PR or 786-O-SR) and pazopanib-resistant orthotopic tumors (which were described in our previous studies [17,18]) than in their corresponding naïve controls (Figs. 1g and 1h).